Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market

Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market by Types of Cancers (Endometrial Adenocarcinoma, Adenosquamous Carcinoma, Papillary Serous Carcinoma, and Uterine Sarcoma), Products (Therapeutics [ Surgery, Immunotherapy, Radiation Therapy, Chemotherapy, and Others] and Diagnostics [Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage, and CT Scan], and Geographies (GCC, South Africa, and Rest of Middle East & Africa)- Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028.

  • Report ID: HC-1964
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 3
  • No. Of Pages: 215
  • Format:
  • Pub. Date: Upcoming
  • Share:

The Middle East & Africa uterine cancer therapeutics & diagnostics market is anticipated to expand at a CAGR of 5.6% during the forecast period, 2021 – 2028. The growth of the market is attributed to rising awareness about uterine disease and increasing number of therapies for the same.

Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market

Uterine cancer is also known as womb cancer. Endometrial cancer and uterine sarcoma are two types of cancer that develops from the tissues of the uterus. Endometrial cancer forms from the lining of the uterus and uterine sarcoma forms from the muscles or support tissue of the uterus. Symptoms of endometrial cancer is unusual vaginal bleeding or pelvis pain, while uterine sarcoma symptoms include vaginal bleeding or a lump in the vagina.

The cancer association of South Africa (CANSA) is an organization that offers integrated services to the people affected by cancer. The mission aims to provide research grants, educating public regarding symptoms, screening and risk reduction, and providing care and support to patients affected by cancer. The department of health in South Africa implemented programs to improve the health of women. Thus, such programs are anticipated to increase early diagnosis procedures.

Market Trends, Drivers, Restraints, and Opportunities:

  • Increasing healthcare expenditure in drug development is expected to drive the market growth.
  • Ongoing technological advancements in medical devices is anticipated to positively impact the market growth.
  • Increasing obesity among women in the region can market growth.
  • Adverse effect of the treatment and high toxicity of drugs can hinder the market.
  • Rising innovation in drug development process is expected to create lucrative opportunities for industry players in the projected timeline.

Scope of the Report

The report on the Middle East & Africa uterine cancer therapeutics & diagnostics market research report includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market - Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Types of Cancers (Endometrial Adenocarcinoma, Adenosquamous Carcinoma, Papillary Serous Carcinoma, and Uterine Sarcoma), Product (Therapeutics [Surgery, Immunotherapy, Radiation Therapy, Chemotherapy, and others] and Diagnostics [Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage, and CT Scan]

Regional Scope

GCC, South Africa, and Rest of Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

 Abbott Laboratories, Merck & Co., Inc, Takeda Pharmaceutical Company Limited, Siemens Healthcare Inc, and F. Hoffmann-La Roche Ltd

Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market Segment Insights

Endometrial adenocarcinoma segment to account a considerable market share

Based on types of cancers, the market is divided into endometrial adenocarcinoma, adenosquamous carcinoma, papillary serous carcinoma, and uterine sarcoma. The endometrial adenocarcinoma segment is anticipated to account for a considerable market share during the forecast period. Increasing obesity in women is a primary factor responsible for the growing incidence of the endometrium carcinoma. Moreover, rising awareness about the cancer is excepted to drive the growth of the market segment. Endometrial cancer produces symptoms at early stages, which in turn, helps the patients to diagnose the cancer at early stage.

Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market

Chemotherapy segment to account a major market share

Based on products, the market is segregated into therapeutics and diagnostics. The therapeutics segment is further segmented into surgery, immunotherapy, radiation therapy, chemotherapy, and others. The diagnostic segment is classified as biopsy, pelvic ultrasound, hysteroscopy, dilation and curettage, and CT Scan. The chemotherapy segment is expected to hold a major market share owing to the lesser number of drugs approved for the treatment of endometrial cancer. This segment is expected to boost due to the high adoption rate of chemotherapy as compared to radiation and surgical treatment. The chemotherapeutic agents such as carboplatin and paclitaxel are recommended as the first line of therapy in the majority of the cancer cases, which is propelling the demand for these drugs.

Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market

The market in South Africa to grow at a rapid pace

In terms of geographies, the market is categorized as GCC, South Africa, and Rest of Middle East & Africa. The market in South Africa is anticipated to exhibit a high CAGR during the forecast period. Increasing prevalence of endometrial cancer, rising awareness about the early diagnosis of cancer, and the presence of the developed healthcare infrastructure are some of the key factors propelling the market growth in the country.

Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market

Segments

Segments Covered in the Report

The Middle East & Africa uterine cancer therapeutics & diagnostics market has been segmented on the basis of

Types of Cancers

  • Endometrial Adenocarcinoma
  • Adenosquamous Carcinoma
  • Papillary Serous Carcinoma
  • Uterine Sarcoma
  • Others

Products

  • Therapeutics
    • Surgery
    • Immunotherapy
    • Radiation Therapy
    • Chemotherapy
    • Others
  • Diagnostics
    • Biopsy
    • Pelvic Ultrasound
    • Hysteroscopy
    • Dilation and Curettage
    • CT Scan

  Geographies

  • GCC
  • South Africa
  • Rest of Middle East & Africa

Key Players

  • Abbott Laboratories
  • Merck & Co., Inc
  • Takeda Pharmaceutical Company Limited
  • Siemens Healthcare Inc
  • F.Hoffmann-La Roche Ltd

Competitive Landscape

Key players operating in the Middle East & Africa uterine cancer therapeutics & diagnostics market includes Abbott Laboratories, Merck & Co., Inc, Takeda Pharmaceutical Company Limited, Siemens Healthcare Inc, and F. Hoffmann-La Roche Ltd.

Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Uterine Cancer Therapeutics & Diagnostics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Uterine Cancer Therapeutics & Diagnostics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Uterine Cancer Therapeutics & Diagnostics Market - Supply Chain
  4.5. Global Uterine Cancer Therapeutics & Diagnostics Market Forecast
     4.5.1. Uterine Cancer Therapeutics & Diagnostics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Uterine Cancer Therapeutics & Diagnostics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Uterine Cancer Therapeutics & Diagnostics Market Absolute $ Opportunity
5. Global Uterine Cancer Therapeutics & Diagnostics Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Uterine Cancer Therapeutics & Diagnostics Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Uterine Cancer Therapeutics & Diagnostics Demand Share Forecast, 2019-2026
6. North America Uterine Cancer Therapeutics & Diagnostics Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Uterine Cancer Therapeutics & Diagnostics Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Uterine Cancer Therapeutics & Diagnostics Demand Share Forecast, 2019-2026
7. Latin America Uterine Cancer Therapeutics & Diagnostics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Uterine Cancer Therapeutics & Diagnostics Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Uterine Cancer Therapeutics & Diagnostics Demand Share Forecast, 2019-2026
8. Europe Uterine Cancer Therapeutics & Diagnostics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Uterine Cancer Therapeutics & Diagnostics Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Uterine Cancer Therapeutics & Diagnostics Demand Share Forecast, 2019-2026
9. Asia Pacific Uterine Cancer Therapeutics & Diagnostics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Uterine Cancer Therapeutics & Diagnostics Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Uterine Cancer Therapeutics & Diagnostics Demand Share Forecast, 2019-2026
10. Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Uterine Cancer Therapeutics & Diagnostics Market: Market Share Analysis
  11.2. Uterine Cancer Therapeutics & Diagnostics Distributors and Customers
  11.3. Uterine Cancer Therapeutics & Diagnostics Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Abbott Laboratories Merck & Co., Inc Takeda Pharmaceutical Company Limited Siemens Healthcare Inc F.Hoffmann-La Roche Ltd

Segments Covered in the Report

The Middle East & Africa uterine cancer therapeutics & diagnostics market has been segmented on the basis of

Types of Cancers

  • Endometrial Adenocarcinoma
  • Adenosquamous Carcinoma
  • Papillary Serous Carcinoma
  • Uterine Sarcoma
  • Others

Products

  • Therapeutics
    • Surgery
    • Immunotherapy
    • Radiation Therapy
    • Chemotherapy
    • Others
  • Diagnostics
    • Biopsy
    • Pelvic Ultrasound
    • Hysteroscopy
    • Dilation and Curettage
    • CT Scan

  Geographies

  • GCC
  • South Africa
  • Rest of Middle East & Africa

Key Players

  • Abbott Laboratories
  • Merck & Co., Inc
  • Takeda Pharmaceutical Company Limited
  • Siemens Healthcare Inc
  • F.Hoffmann-La Roche Ltd

Key players operating in the Middle East & Africa uterine cancer therapeutics & diagnostics market includes Abbott Laboratories, Merck & Co., Inc, Takeda Pharmaceutical Company Limited, Siemens Healthcare Inc, and F. Hoffmann-La Roche Ltd.

Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market

Buy Report